Gilead Sciences

AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending
AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending
Fierce Pharma
DTC ads
television ads
AbbVie
Humira
Gilead Sciences
Truvada
Allergan
Botox
Flag link:
Gilead, Galapagos share 52-week update on filgotinib
Gilead, Galapagos share 52-week update on filgotinib
Fierce Biotech
Gilead Sciences
Galapagos
filgotinib
clinical trials
rheumatoid arthritis
Flag link:
Biopharma M&A: deal-depressed third quarter leaves nowhere to hide
Biopharma M&A: deal-depressed third quarter leaves nowhere to hide
EP Vantage
M&A
Lundbeck
Alder Biopharmaceuticals
Gilead Sciences
Galapagos
Vertex Pharmaceuticals
Semma
Swedish Orphan Biovitrum
Dova Pharmaceuticals
Novartis
IFM
Flag link:
Chasing AbbVie, Gilead files for approval of filgotinib in Japan
Chasing AbbVie, Gilead files for approval of filgotinib in Japan
Fierce Biotech
Gilead Sciences
JAK inhibitors
Japan
filgotinib
Galapagos
AbbVie
Flag link:
After more than a year, Gilead finds new chief medical officer
After more than a year, Gilead finds new chief medical officer
Biopharma Dive
Gilead Sciences
Roche
Genentech
Flag link:
Gilead scores PrEP approval for Descovy — kicking off marketing push before Truvada generics swarm
Gilead scores PrEP approval for Descovy — kicking off marketing push before Truvada generics swarm
Endpoints
Gilead Sciences
Descovy
HIV
PrEP
FDA
Truvada
generics
Flag link:
3 Biotechs With the Biggest Cash Stockpiles
3 Biotechs With the Biggest Cash Stockpiles
Motley Fool
biotech
cash
Gilead Sciences
Amgen
Celgene
Flag link:
HIV-focused Gilead launches fund, pledges $2M to help transgender people
HIV-focused Gilead launches fund, pledges $2M to help transgender people
Fierce Pharma
Gilead Sciences
HIV
transgender
philanthropy
Flag link:
4 Key Questions for Gilead Sciences' New CEO
4 Key Questions for Gilead Sciences' New CEO
Motley Fool
Gilead Sciences
Daniel O'Day
Pharma CEOs
Flag link:
FDA issues safety warning for newer hepatitis C drugs following patient deaths
FDA issues safety warning for newer hepatitis C drugs following patient deaths
Biopharma Dive
FDA
hepatitis C
FAERS
AbbVie
Mavyret
Merck
Zepatier
Gilead Sciences
Vosevi
Flag link:
Gilead, Galapagos finalise £4.1bn research and development deal
Gilead, Galapagos finalise £4.1bn research and development deal
Pharmaceutical Business Review
Gilead Sciences
Galapagos
R&D
Flag link:
AbbVie's Rinvoq label portends safety warnings for future JAKs—including Gilead's
AbbVie's Rinvoq label portends safety warnings for future JAKs—including Gilead's
Fierce Pharma
JAK inhibitors
AbbVie
Rinvoq
FDA
Gilead Sciences
Flag link:
FDA AdCom backs Gilead's move to expand Descovy label — but stops short of endorsing broad PrEP use
FDA AdCom backs Gilead's move to expand Descovy label — but stops short of endorsing broad PrEP use
Endpoints
FDA
Gilead Sciences
HIV
Descovy
PrEP
Flag link:
Regulators, Gilead at odds over HIV drug's use in women
Regulators, Gilead at odds over HIV drug's use in women
Biopharma Dive
Gilead Sciences
HIV
Descovy
Flag link:
Gilead looks to Galapagos deal to double research capacity
Gilead looks to Galapagos deal to double research capacity
Fierce Biotech
Gilead Sciences
Daniel O'Day
Galapagos
R&D
Flag link:
Gilead Sciences Reports Improving Revenue in the 2nd Quarter
Gilead Sciences Reports Improving Revenue in the 2nd Quarter
Motley Fool
Gilead Sciences
earnings
Biktarvy
Flag link:
Gilead's exec search won't hurt its deal search: CEO
Gilead's exec search won't hurt its deal search: CEO
Fierce Pharma
Gilead Sciences
M&A
Daniel O'Day
Flag link:
Busy Gilead crew throws struggling biotech a lifeline, with some cash upfront and hundreds of millions in biobucks for HIV deal
Busy Gilead crew throws struggling biotech a lifeline, with some cash upfront and hundreds of millions in biobucks for HIV deal
Endpoints
Gilead Sciences
Durect
HIV
hepatitis B
extended release
Flag link:
Novartis licenses out early antiviral work to Gilead
Novartis licenses out early antiviral work to Gilead
Fierce Biotech
Gilead Sciences
Novartis
antivirals
Flag link:
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
Investors Business Daily
Bristol-Myers Squibb
Celgene
M&A
Otezla
Gilead Sciences
Amgen
Regeneron
Eli Lilly
JNJ
Flag link:

Pages